"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 20
Inclusion Criteria
- who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
- patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
- who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
- patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
Exclusion Criteria
- pregnancy
- refusing to give informed consent
- active Alcohol user
- ...
- pregnancy
- refusing to give informed consent
- active Alcohol user
- breast feeding
- Severe dysfunction of liver and kidney
- presence of decompensate cirrhosis
- coinfection with Hepatitis A,C,D viruses or HIV
- Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study
Summary
- Conditions
- Hepatitis C Virus
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Inclusion Criteria
- who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
- patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
- who never achieved undetectable HCV RNA during treatment of a minimum duration of 24 weeks
- patients who failed to achieve a decline of 2 log HCV RNA IU/ml after 12 weeks of treatment
Exclusion Criteria
- pregnancy
- refusing to give informed consent
- active Alcohol user
- ...
- pregnancy
- refusing to give informed consent
- active Alcohol user
- breast feeding
- Severe dysfunction of liver and kidney
- presence of decompensate cirrhosis
- coinfection with Hepatitis A,C,D viruses or HIV
- Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study
Tracking Information
- NCT #
- NCT02058173
- Collaborators
- Not Provided
- Investigators
- Study Chair: Kamran B Lankarani, M.D Health policy research center
Get Well Soon